Search Results - "Berenato, R."

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis by Cremolini, C., Di Bartolomeo, M., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., Sartore-Bianchi, A., Fontanini, G., Milione, M., Lauricella, C., Siena, S., Falcone, A., de Braud, F., Loupakis, F., Pietrantonio, F.

“…While the negative prognostic role of BRAF V600E mutation in metastatic colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596…”
Get full text

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research by Pietrantonio, F., Caporale, M., Morano, F., Scartozzi, M., Gloghini, A., De Vita, F., Giommoni, E., Fornaro, L., Aprile, G., Melisi, D., Berenato, R., Mennitto, A., Volpi, C. C., Laterza, M. M., Pusceddu, V., Antonuzzo, L., Vasile, E., Ongaro, E., Simionato, F., de Braud, F., Torri, V., Di Bartolomeo, M.

“…Mechanisms of acquired resistance to trastuzumab‐based treatment in gastric cancer are largely unknown. In this study, we analyzed 22 pairs of tumor samples…”
Get full text

Toward the molecular dissection of peritoneal pseudomyxoma by Pietrantonio, F., Perrone, F., Mennitto, A., Gleeson, E.M., Milione, M., Tamborini, E., Busico, A., Settanni, G., Berenato, R., Caporale, M., Morano, F., Bossi, I., Pellegrinelli, A., Di Bartolomeo, M., de Braud, F., Baratti, D., Bowne, W.B., Kusamura, S., Deraco, M.

“…Outcome of pseudomyxoma peritonei (PMP) after cytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC) is heterogeneous even after…”
Get full text

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study by Cremolini, C., Morano, F., Moretto, R., Berenato, R., Tamborini, E., Perrone, F., Rossini, D., Gloghini, A., Busico, A., Zucchelli, G., Baratelli, C., Tamburini, E., Tampellini, M., Sensi, E., Fucà, G., Volpi, C., Milione, M., Di Maio, M., Fontanini, G., De Braud, F., Falcone, A., Pietrantonio, F.

“…Refining the selection of metastatic colorectal cancer patients candidates for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies beyond RAS…”
Get full text

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram by Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., Loupakis, F., Spada, D., Cinieri, S., Beretta, G., Falcone, A., de Braud, F., Cremolini, C.

“…Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC)…”
Get full text

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation by Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., Raimondi, A., Nichetti, F., Martinetti, A., Battaglia, L., Perrone, F., Pruneri, G., Falcone, A., Di Bartolomeo, M., de Braud, F., Di Nicolantonio, F., Cremolini, C., Pietrantonio, F.

“…Non-randomized studies showed that temozolomide (TMZ) achieves an average 10% response rate in heavily pretreated metastatic colorectal cancer (mCRC) patients…”
Get full text

First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study by Pietrantonio, F., Morano, F., Corallo, S., Raimondi, A., Loupakis, F., Cremolini, C., Smiroldo, V., Berenato, R., Bianchi, A. Sartore, Tampellini, M., Bustreo, S., Clavarezza, M., Murialdo, R., Zaniboni, A., Tomasello, G., Peverelli, G., Antoniotti, C., Procaccio, L., Cinieri, S., Antonuzzo, L., Di Bartolomeo, M., de Braud, F.

Get full text

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study by Raimondi, A., Fucà, G., Leone, A.G., Lonardi, S., Antoniotti, C., Smiroldo, V., Amatu, A., Tampellini, M., Ritorto, G., Murialdo, R., Clavarezza, M., Zaniboni, A., Berenato, R., Ratti, M., Corallo, S., Morano, F., Di Bartolomeo, M., Di Maio, M., Pietrantonio, F.

“…The safety and efficacy outcome of elderly metastatic colorectal cancer (mCRC) patients fit enough to receive combination chemotherapy plus biological agents…”
Get full text

2265 Capecitabine, oxaliplatin and irinotecan (COI regimen) as perioperative treatment of resectable gastric or gastroesophafageal junction (GEJ) cancer by Berenato, R, Pellegrinelli, A, Pietrantonio, F, Niger, M, Caporale, M, De Braud, F, Ricchini, F, Maggi, C, Di Bartolomeo, M

Get full text

Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study by Rossini, D., Cremolini, C., Morano, F., Berenato, R., Tamborini, E., Perrone, F., Moretto, R., Gloghini, A., Busico, A., Zucchelli, G., Baratelli, C., Tamburini, E., Fucà, G., Volpi, C., Milione, M., Di Maio, M., Fontanini, G., de Braud, F., Falcone, A., Pietrantonio, F.

Get full text

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab by Falvella, F S, Cremolini, C, Miceli, R, Nichetti, F, Cheli, S, Antoniotti, C, Infante, G, Martinetti, A, Marmorino, F, Sottotetti, E, Berenato, R, Caporale, M, Colombo, A, de Braud, F, Di Bartolomeo, M, Clementi, E, Loupakis, F, Pietrantonio, F

“…Single-nucleotide polymorphisms (SNPs) related to hereditary thrombophilia were investigated as risk factors for thromboembolism in cancer patients. Their…”
Get full text

2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with “non diffusive type” gastric carcinoma radically resected by Di Bartolomeo, M, Pellegrinelli, A, Iacovelli, R, Pietrantonio, F, Berenato, R, Caporale, M, Niger, M, Barbera, M, Labianca, R, Martoni, A, Rosati, G, Nitti, D, Boni, C, Bajetta, E

Get full text

2190 Discovery of new molecular subtypes of non-hypermutated metastatic colorectal cancer (mCRC) through a next-generation sequencing (NGS) approach by Pietrantonio, F, Perrone, F, Cremolini, C, Orlandi, A, Niger, M, Caporale, M, Berenato, R, Antoniotti, C, Loupakis, F, Tamborini, E, Milione, M, Settanni, G, Busico, A, De Braud, F, Di Bartolomeo, M

Get full text

416 Variant Alleles in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) or Methylenetetrahydrofolate Reductase (MTHFR) and risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients by Falvella, F.S, Cremolini, C, Miceli, R, Nichetti, F, Cheli, S, Antoniotti, C, Infante, G, Martinetti, A, Loupakis, F, Bartolomeo, M. Di, Marmorino, F, Sottotetti, E, Bossi, I, Berenato, R, Caporale, M, Niger, M, Colombo, A, Braud, F. De, Clementi, E, Pietrantonio, F

Get full text

2366 Metronomic capecitabine and bevacizumab is an active combination in patients with relapsed peritoneal pseudomyxoma by Maggi, C, De Braud, F, Di Bartolomeo, M, Perrone, F, Tamborini, E, Milione, M, Deraco, M, Kusamura, S, Baratti, D, Berenato, R, Caporale, M, Consonni, P.V, Niger, M, Bossi, I, Leo, E, Pelosi, G, Pietrantonio, F

Get full text

Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study by Muscaritoli, Maurizio, Lucia, Simone, Farcomeni, Alessio, Lorusso, Vito, Saracino, Valeria, Barone, Carlo, Plastino, Francesca, Gori, Stefania, Magarotto, Roberto, Carteni, Giacomo, Chiurazzi, Bruno, Pavese, Ida, Marchetti, Luca, Zagonel, Vittorina, Bergo, Eleonora, Tonini, Giuseppe, Imperatori, Marco, Iacono, Carmelo, Maiorana, Luigi, Pinto, Carmine, Rubino, Daniela, Cavanna, Luigi, Di Cicilia, Roberto, Gamucci, Teresa, Quadrini, Silvia, Palazzo, Salvatore, Minardi, Stefano, Merlano, Marco, Colucci, Giuseppe, Marchetti, Paolo

“…In cancer patients, malnutrition is associated with treatment toxicity, complications, reduced physical functioning, and decreased survival. The Prevalence of…”
Get full text

Perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM): Preliminary safety and activity by Mennitto, A., Cotsoglou, C., Caporale, M., Scotti, M., Berenato, R., Coppa, J., Di Bartolomeo, M., Milione, M., Bossi, I., de Braud, F., Mazzaferro, V., Filippo, P.

Get full text

Patients with borderline resectable colorectal cancer liver metastases (CLM): preliminary safety and activity of perioperative triplet chemotherapy plus bevacizumab (bev) by Mennitto, A., Cotsoglou, C., Caporale, M., Scotti, M., Berenato, R., Coppa, J., Di Bartolomeo, M., Milione, M., Bossi, I., de Braud, F., Mazzaferro, V., Pietrantonio, F.

Get full text

O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study by Pietrantonio, F, Morano, F, Corallo, S, Raimondi, A, Loupakis, F, Cremolini, C, Smiroldo, V, Berenato, R, Bianchi, A Sartore, Tampellini, M, Bustreo, S, Clavarezza, M, Murialdo, R, Zaniboni, A, Tomasello, G, Peverelli, G, Antoniotti, C, Procaccio, L, Cinieri, S, Antonuzzo, L, Di Bartolomeo, M, de Braud, F

Get full text

Capecitabine, oxaliplatin and irinotecan (COI regimen) as perioperative treatment of resectable gastric or gastroesophageal junction (GEJ) cancer by Berenato, R., Pietrantonio, F., Niger, M., Caporale, M., Ricchini, F., Maggi, C., Bossi, I., Consonni, P.V., de Braud, F., Di Bartolomeo, M.

Get full text